| Display title | Medicine:Risk Evaluation and Mitigation Strategies |
| Default sort key | Risk Evaluation and Mitigation Strategies |
| Page length (in bytes) | 6,940 |
| Namespace ID | 3048 |
| Namespace | Medicine |
| Page ID | 540610 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Raymond Straus |
| Date of page creation | 18:38, 25 June 2023 |
| Latest editor | imported>Raymond Straus |
| Date of latest edit | 18:38, 25 June 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. The REMS program was... |
